STONY BROOK, NY --(Marketwired - September 14, 2016) - Applied DNA Sciences (Applied DNA), Inc. (
Speaking at the conference about the role of innovation in the supply chain will be Applied DNA's Chief of Business Development, Mr. Bob Miglani. A former 23 year executive from Pfizer Inc. in New York, Mr. Miglani will share insights and trends from the textile industry which might offer learnings for pharmaceutical companies as to new technologies and approaches to reducing risk in the pharmaceutical supply chain.
"We are living in disruptive times. This is especially true for those who are responsible for sourcing and supply chain management in a pharmaceutical company. From ensuring compliance with international laws to sourcing quality raw ingredients from around the world to fighting counterfeit trade, pharmaceutical supply chain managers face enormous challenges. That's why we at Applied DNA help supply chain managers ensure quality, authenticity and compliance through the adoption of our SigNature DNA Molecular Taggants," stated Mr. Miglani.
Powered by unique and customized botanical-based SigNature DNA, Applied DNA's molecular taggants can be deployed on the pharmaceutical inks which imprint on the tablet or capsule, or on the coating on tablets, which ensure a mark of authenticity for regulatory inspectors and patients alike. Applied DNA's SigNature DNA Molecular Taggants satisfy the principles established by FDA Guidelines for inclusion in pharmaceuticals.
Applied DNA can also DNA-mark other elements of a finished product including bulk Active Pharmaceutical Ingredient (API), cellulosic excipients (bulk fillers) that are used in almost all drug tablets and the commercial binders and enteric coatings that hold prescription and Over-the-Counter (OTC) drug tablets together. This unique, multi-factor identification enables verification of its authenticity at any point in the supply chain. http://www.adnas.com/sites/default/files/down...aphic1.pdf
Governments around the world have accelerated their adoption of drug quality regulations in the effort to ensure product integrity and protect patient safety. By seamlessly integrating SigNature DNA Molecular Taggants into serialization efforts already underway, pharmaceutical companies can now further reduce risk and enhance safety for their patients.
"The scalability of SigNature DNA for pharmaceuticals solves many supply chain challenges as recently highlighted in Scientific American *. Many of our clients that are using SigNature DNA know that forensic tagging and authentication will protect them from the risk of legal liability and product recall while maintaining profitability and market differentiation," stated Dr. James A. Hayward, President and CEO, APDN.
* For more information please see article "Authentic Drugs Tagged with Plant DNA Could Help Snare Fake Meds" published in Scientific American on January 12, 2016.
About Applied DNA Sciences
Applied DNA Sciences makes life real and safe by providing biotechnology-driven solutions to help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. Patented botanical DNA solutions can be used to identify, tag, track, and trace products, to help assure authenticity, traceability and quality of products. SigNature ® DNA is at the heart of a family of uncopyable, security and authentication solutions such as SigNature ® T and fiberTyping ® , for textiles and apparel, DNAnet ® , for anti-theft and loss prevention, and digitalDNA ® , providing powerful track and trace. All provide a forensic chain of evidence, and can be used to prosecute perpetrators.Go to adnas.com for more information, events and to learn more about how Applied DNA Sciences makes life real and safe. Common stock listed on NASDAQ under the symbol APDN, and warrants are listed under the symbol APDNW.
Forward Looking Statements
The statements made by APDN in this press release may be "forward-looking" in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe APDN's future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN's SEC reports and filings, including our Annual Report on Form 10-K filed on December 14, 2015,and our subsequent quarterly report on Form 10-Q filed on February 10, 2016, May 12, 2016 and August 11, 2016 , which are available at www.sec.gov . APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.
Investor contact: Debbie Bailey 631-240-8817 debbie.bailey@adnas.com media contact: Susan Forman Dian Griesel Int'l. 212-825-3210 sforman@dgicomm.com program contact: Bob Miglani bob.miglani@adnas.com web: www.adnas.com twitter: @APDN
